These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 28155702)

  • 21. Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring.
    Little K; Leang SK; Butler J; Baas C; Harrower B; Mosse J; Barr IG; Hurt AC
    Euro Surveill; 2015; 20(45):. PubMed ID: 26608955
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Promising Anti-influenza Properties of Active Constituent of Withania somnifera Ayurvedic Herb in Targeting Neuraminidase of H1N1 Influenza: Computational Study.
    Cai Z; Zhang G; Tang B; Liu Y; Fu X; Zhang X
    Cell Biochem Biophys; 2015 Jul; 72(3):727-39. PubMed ID: 25627548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in in vitro susceptibility of influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution in the human host.
    Thompson CI; Barclay WS; Zambon MC
    J Antimicrob Chemother; 2004 May; 53(5):759-65. PubMed ID: 15028666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against influenza virus isolates in the 2011-2012 season in Japan.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2014 Feb; 20(2):77-80. PubMed ID: 24560563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis of C-4-modified zanamivir analogs as neuraminidase inhibitors and their anti-AIV activities.
    Ye D; Shin WJ; Li N; Tang W; Feng E; Li J; He PL; Zuo JP; Kim H; Nam KY; Zhu W; Seong BL; No KT; Jiang H; Liu H
    Eur J Med Chem; 2012 Aug; 54():764-70. PubMed ID: 22795831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice.
    Ferraris O; Kessler N; Lina B
    Antiviral Res; 2005 Oct; 68(1):43-8. PubMed ID: 16125799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds.
    Abed Y; Baz M; Boivin G
    Antivir Ther; 2006; 11(8):971-6. PubMed ID: 17302366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. E119D Neuraminidase Mutation Conferring Pan-Resistance to Neuraminidase Inhibitors in an A(H1N1)pdm09 Isolate From a Stem-Cell Transplant Recipient.
    L'Huillier AG; Abed Y; Petty TJ; Cordey S; Thomas Y; Bouhy X; Schibler M; Simon A; Chalandon Y; van Delden C; Zdobnov E; Boquete-Suter P; Boivin G; Kaiser L
    J Infect Dis; 2015 Dec; 212(11):1726-34. PubMed ID: 25985905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiviral susceptibility profile of influenza A viruses; keep an eye on immunocompromised patients under prolonged treatment.
    Kossyvakis A; Mentis AA; Tryfinopoulou K; Pogka V; Kalliaropoulos A; Antalis E; Lytras T; Meijer A; Tsiodras S; Karakitsos P; Mentis AF
    Eur J Clin Microbiol Infect Dis; 2017 Feb; 36(2):361-371. PubMed ID: 27848039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamic behavior of avian influenza A virus neuraminidase subtype H5N1 in complex with oseltamivir, zanamivir, peramivir, and their phosphonate analogues.
    Udommaneethanakit T; Rungrotmongkol T; Bren U; Frecer V; Stanislav M
    J Chem Inf Model; 2009 Oct; 49(10):2323-32. PubMed ID: 19780597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Homology modeling, docking, and molecular dynamics reveal HR1039 as a potent inhibitor of 2009 A(H1N1) influenza neuraminidase.
    Wang YT; Chan CH; Su ZY; Chen CL
    Biophys Chem; 2010 Mar; 147(1-2):74-80. PubMed ID: 20045243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In silico identification of the potential drug resistance sites over 2009 influenza A (H1N1) virus neuraminidase.
    Liu H; Yao X; Wang C; Han J
    Mol Pharm; 2010 Jun; 7(3):894-904. PubMed ID: 20420444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-based design and synthesis of C-1- and C-4-modified analogs of zanamivir as neuraminidase inhibitors.
    Feng E; Shin WJ; Zhu X; Li J; Ye D; Wang J; Zheng M; Zuo JP; No KT; Liu X; Zhu W; Tang W; Seong BL; Jiang H; Liu H
    J Med Chem; 2013 Feb; 56(3):671-84. PubMed ID: 23330908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Computational analysis and modeling the effectiveness of 'Zanamivir' targeting neuraminidase protein in pandemic H1N1 strains.
    Gupta SK; Gupta SK; Smita S; Srivastava M; Lai X; Schmitz U; Rahman Q; Wolkenhauer O; Vera J
    Infect Genet Evol; 2011 Jul; 11(5):1072-82. PubMed ID: 21463714
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms of the action of povidone-iodine against human and avian influenza A viruses: its effects on hemagglutination and sialidase activities.
    Sriwilaijaroen N; Wilairat P; Hiramatsu H; Takahashi T; Suzuki T; Ito M; Ito Y; Tashiro M; Suzuki Y
    Virol J; 2009 Aug; 6():124. PubMed ID: 19678928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.
    Shobugawa Y; Saito R; Sato I; Kawashima T; Dapat C; Dapat IC; Kondo H; Suzuki Y; Saito K; Suzuki H
    J Infect Chemother; 2012 Dec; 18(6):858-64. PubMed ID: 22644080
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A surface plasmon resonance assay for measurement of neuraminidase inhibition, sensitivity of wild-type influenza neuraminidase and its H274Y mutant to the antiviral drugs zanamivir and oseltamivir.
    Somasundaram B; Fee CJ; Fredericks R; Watson AJ; Fairbanks AJ; Hall RJ
    J Mol Recognit; 2015 Sep; 28(9):521-7. PubMed ID: 25727669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro antiviral effects and 3D QSAR study of resveratrol derivatives as potent inhibitors of influenza H1N1 neuraminidase.
    Li C; Fang JS; Lian WW; Pang XC; Liu AL; Du GH
    Chem Biol Drug Des; 2015 Apr; 85(4):427-38. PubMed ID: 25185493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, and in vitro biological evaluation of novel 6-methyl-7-substituted-7-deaza purine nucleoside analogs as anti-influenza A agents.
    Lin C; Sun C; Liu X; Zhou Y; Hussain M; Wan J; Li M; Li X; Jin R; Tu Z; Zhang J
    Antiviral Res; 2016 May; 129():13-20. PubMed ID: 26802557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of the MDCK cell selected neuraminidase D151G mutation on the drug susceptibility assessment of influenza A(H3N2) viruses.
    Mishin VP; Sleeman K; Levine M; Carney PJ; Stevens J; Gubareva LV
    Antiviral Res; 2014 Jan; 101():93-6. PubMed ID: 24239666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.